TIL Therapy: A New Melanoma Treatment 30 Years in the Making
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
Progress Against Cancer
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.
Researchers at the AACR Annual Meeting 2024 examined new treatment options for brain tumors.
Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
Researchers are exploring new options for kidney cancer treatments.
February’s selections include a modified Zika virus to treat cancer, insights into treatment resistance, and more.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More